Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Journal of Medical Economics|January 4, 2021
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesiaMichael L Ganz, Ameya Chavan, Rahul Dhanda, et al.
Journal of Medical Economics|December 23, 2014
Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritisMichael L Ganz, Brian Bekker Hansen, Xavier Valencia, et al.
Medical Care|July 25, 2006
Community preferences for health states associated with intimate partner violenceEve Wittenberg, Erika L Lichter, Michael L Ganz, et al.
American Health & Drug Benefits|May 4, 2017
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United StatesJoseph Lee, Ryan Pelkey, Julieanna Gubitosa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 11, 2018
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 YearsQian Li, Rahul Ganguly, Michael L Ganz, et al.
Current Medical Research and Opinion|September 21, 2016
Real-world characteristics of elderly patients with overactive bladder in the United StatesMichael L Ganz, Jieruo Liu, Kelly H Zou, et al.
Advances in Therapy|September 24, 2014
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort studyAbhishek S Chitnis, Michael L Ganz, Nicole Benjamin, et al.
The Milbank Quarterly|September 17, 1998
Social epidemiology and the fundamental cause concept: on the structuring of effective cancer screens by socioeconomic statusB G Link, M E Northridge, J C Phelan, et al.
Human Vaccines & Immunotherapeutics|December 16, 2024
Retrospective analysis of health and economic burden among commercially-insured individuals diagnosed with invasive meningococcal disease in the United StatesOscar Herrera-Restrepo, Marta Kwiatkowska, Samuel Huse, et al.
Pageof 9